76.40
+2.96%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CHO Pharma
Its shares trade on Taipei Exchange under the ticker 6586.TWO. It has been listed since 27 September 2017. In the fiscal year to 31 December 2025, it reported revenue of TWD 1.4m and a net loss of TWD 290.0m. At that date it held total assets of TWD 2.57bn and shareholders' equity of TWD 2.46bn.
CHO Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of innovative products based on the proprietary glycan engineering technologies. The company is headquartered in Taipei City, Taipei. The company went IPO on 2017-09-27. The company’s technology and development can be divided into eight categories according to its patent features, including homogeneous antibody drugs, monoclonal antibodies of cancers and immune-related diseases, carbohydrate-related vaccines and drugs, anti-influenza drugs, the development and application of Saccharin tablets, the development and application of sugar probes, the synthesis identification development and application of sugar molecular, as well as the derivative patents of innovation development plans.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 27 Sept 2017
- Website
- chopharma.com ↗
Leadership
Pay as last reported
- Mr. Chao-Long ChenChairman of the Board, since 2017
- Ms. I-Pei ChouFinance Manager, Corporate Governance Officer
- Mr. Chung-Yi WuGeneral Manager, Director, since 2019
- Ms. Lingmei WangDeputy General Manager
- Jianzhang ChenDirector
- Shunling ChenDirector
- Baolin MaDirector
- Mr. Richard TsaiDirector
- Xuanda LiuIndependent Director
- Zhengjian QiuIndependent Director
- Songliang YuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CHO Pharma's glycan engineering technology enables innovative pharmaceutical products in Taipei City.
- The company's eight patent categories cover diverse therapeutic areas including cancer and immune diseases.
- CHO Pharma's IPO on 27 September 2017 established a strong market foundation.
Weaknesses
- The company's focus on glycan engineering may limit broader market expansion opportunities.
- Limited commercialization of carbohydrate-related vaccines and drugs in global markets.
- CHO Pharma's operations are concentrated in Taipei City with minimal international presence.
Opportunities
- Growing demand for cancer and immune-related monoclonal antibodies in the Health Care sector.
- Expansion of anti-influenza drugs in the Asia-Pacific region.
- Increased application of sugar probes in pharmaceutical research and development.
Threats
- Intense competition from established pharmaceutical companies in the Health Care sector.
- Regulatory challenges for glycan engineering-based drug approvals in multiple countries.
- Potential market saturation in the development of carbohydrate-related vaccines and drugs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.